NetScientific PLC (LON:NSCI) said its investee company Vortex Biosciences has begun the commercial launch of its VTX1 Liquid Biopsy System.
The fully-automated technology offers a breakthrough in early cancer detection in that it is able to collect circulating tumour cells (CTC) from the bloodstream that provide the tell-tale sign of the killer disease.
"We believe the technology has several key advantages over current approaches to CTC isolation and has the potential to make a meaningful impact on cancer research and assist the development of innovative diagnostics and therapeutics," said NetScientific chief executive François Martelet.
"The commercial launch is a critical milestone for Vortex and brings our portfolio company closer to significant value creation."
The AIM-listed investment company owns 95% of Votex having invested just over £13mln in the business.
The official launch took place in San Francisco at the Molecular Medicine Tri Conference.